Eledon pharmaceuticals to present updated data from ongoing phase 1b trial of tegoprubart in patients undergoing kidney transplantation at the american transplant congress

Irvine, calif., may 09, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced that the company will participate in the american transplant congress (atc) taking place in philadelphia, pa from june 1-5, 2024.
ELDN Ratings Summary
ELDN Quant Ranking